Effect of Everolimus Versus Tacrolimus On Left Ventricular Hypertrophy in Renal Transplant Patients On Maintenance

J. Morales,¹ J. Pascual,² A. Sánchez-Fructuoso,³ D. Serón,⁴ J. Díaz,⁵ F. Oppenheimer,⁶ M. Rengel,⁷ D. Hernández,⁸ J. Cruzado,⁹ On Behalf of Evita Study Group.

¹Fund. Investigación, H. 12 Octubre, Madrid, Spain
²S. Nefrología, H. del Mar, Barcelona, Spain
³S. Nefrología, H. Clínico San Carlos, Madrid, Spain
⁴S. Nefrología, H. Vall Hebrón, Barcelona, Spain
⁵S. Nefrología, Fund. Puigvert, Barcelona, Spain
⁶Unidad Trasp. Renal, H. Clínic i Provincial Barcelona, Barcelona, Spain
⁷S. Urología, H. Gregorio Marañón, Madrid, Spain
⁸S. Nefrología, H. Carlos Haya, Málaga, Spain
⁹S. Nefrología, H. Bellvitge. IDIBELL, Barcelona, Spain.

Meeting: 2015 American Transplant Congress

Abstract number: A176

Keywords: Kidney transplantation

Session Information

Session Name: Poster Session A: Kidney: Cardiovascular and Metabolic

Session Type: Poster Session

Date: Saturday, May 2, 2015

Session Time: 5:30pm-7:30pm

Presentation Time: 5:30pm-7:30pm

Location: Exhibit Hall E

PURPOSE: To compare the efficacy of everolimus (EVL) in improving LVH in a regimen with mycophenolic acid (MPA) vs tacrolimus (TAC)+MPA in maintenance renal transplant recipients. METHODS: Multicentre, open-label, randomized, parallel-group, 24 months follow-up. Patients 18-70 years, first/second renal transplant >6months-≤3 years on TAC+MPA, were included. Patients with serum creatinine ≥2 mg/l; glomerular filtration rate (GFR) ≤40 ml/min; proteinuria ≥500 mg/24h, severe rejection and PRA ≥20%, were excluded. LVH was defined by Zoccali's formula. RESULTS: 60 patients were included (28 EVL;32 TAC; ITT population). Both groups had similar baseline characteristics: mean(SD) age 48.3(12.5) years; 58.3% men; BMI 26.5(4.3) kg/m²; 90.0% first transplant. 83.3% had 0% PRA. Systemic steroid treatments were similar (67.9% EVL;71.9% TAC). Mean time since transplantation was 1.5(0.8) years. Proteinuria at baseline was similar (EVL: 0.21;TAC: 0.17 g/24h). LVH values and GFR are described in Table 1.

**Table1**. LVH and GFR by visit. ITT population
	TAC (N=32)	EVL (N=28)	Total (N=60)
LVH¹, n(%)
Baseline	19(59.4)	16(57.1)	35(58.3)
Month-12	20(62.5)	17(60.7)	37(61.6)
Month-24	12(37.5)	12(42.9)	24(40.0)
GFR² (ml/min/1.73m²), mean(SD)
Baseline	59.9(13.4)	58.7(15.0)	59.3(14.0)
Month-6	56.0(11.2)	62.8(18.1)	59.1(15.0)
Month-12	57.8(11.4)	61.2(19.2)	59.4(15.5)
Month-24	57.7(10.5)	60.8(17.4)	59.2(14.0)

¹No differences between treatments were observed, but a LVH decrease at month-24 vs baseline in each group was observed. ²No differences between treatments were observed, but a significant improvement in EVL at month-6 vs baseline was observed (p=0.0143) and was maintained at month-12 and month-24.No cell/humoral rejection/graft loss in EVL or TAC occurred. Adverse events: 132 EVL vs 74 TAC (8 and 5 SAEs, respectively). CONCLUSIONS: LVH was reduced at month-24 in EVL and TAC groups. Even in patient with GFR>40 ml/min, conversion from TAC to EVL resulted in better preservation of renal function.

To cite this abstract in AMA style:

Morales J, Pascual J, Sánchez-Fructuoso A, Serón D, Díaz J, Oppenheimer F, Rengel M, Hernández D, Cruzado J. Effect of Everolimus Versus Tacrolimus On Left Ventricular Hypertrophy in Renal Transplant Patients On Maintenance [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/effect-of-everolimus-versus-tacrolimus-on-left-ventricular-hypertrophy-in-renal-transplant-patients-on-maintenance/. Accessed June 6, 2025.

« Back to 2015 American Transplant Congress